Sana Biotechnology (NASDAQ:SANA – Get Free Report) had its price target dropped by analysts at Citigroup to $11.00 in a report released on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup‘s price target would indicate a potential upside of 480.47% from the stock’s previous close.
SANA has been the topic of a number of other reports. Weiss Ratings downgraded shares of Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. Bank of America reduced their price objective on shares of Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Wall Street Zen raised shares of Sana Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Finally, TD Cowen raised shares of Sana Biotechnology to a “strong-buy” rating in a research note on Monday, August 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Sana Biotechnology has a consensus rating of “Moderate Buy” and a consensus target price of $9.83.
View Our Latest Report on Sana Biotechnology
Sana Biotechnology Stock Performance
SANA traded down $0.12 during midday trading on Monday, hitting $1.90. The company had a trading volume of 2,464,938 shares, compared to its average volume of 3,167,266. The firm’s 50-day simple moving average is $2.72 and its 200-day simple moving average is $3.29. The company has a market capitalization of $567.81 million, a PE ratio of -3.58 and a beta of 2.30. Sana Biotechnology has a twelve month low of $1.86 and a twelve month high of $5.49.
Sana Biotechnology (NASDAQ:SANA – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. As a group, sell-side analysts anticipate that Sana Biotechnology will post -0.57 EPS for the current fiscal year.
Hedge Funds Weigh In On Sana Biotechnology
Hedge funds have recently made changes to their positions in the stock. Palumbo Wealth Management LLC boosted its holdings in shares of Sana Biotechnology by 39.6% during the third quarter. Palumbo Wealth Management LLC now owns 83,462 shares of the company’s stock worth $243,000 after purchasing an additional 23,689 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Sana Biotechnology in the 3rd quarter valued at approximately $45,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Sana Biotechnology by 23.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 54,622 shares of the company’s stock worth $159,000 after acquiring an additional 10,332 shares during the period. T3 Companies LLC increased its position in Sana Biotechnology by 162.8% during the third quarter. T3 Companies LLC now owns 29,700 shares of the company’s stock valued at $87,000 after acquiring an additional 18,400 shares during the last quarter. Finally, Abel Hall LLC purchased a new stake in Sana Biotechnology during the third quarter valued at approximately $35,000. 88.23% of the stock is currently owned by hedge funds and other institutional investors.
Sana Biotechnology Company Profile
Sana Biotechnology, Inc. is a clinical-stage biotechnology company founded in 2018 and headquartered in Seattle. It develops engineered cells intended to treat a range of diseases, including cancer, autoimmune disorders and conditions that may be addressed through cell replacement. The company’s research focuses on modifying cells to improve their therapeutic properties, including approaches designed to help transplanted cells evade immune rejection. Its programs include engineered immune-cell therapies and cell-replacement treatments, such as work involving insulin-producing cells for type 1 diabetes.
Further Reading
- Five stocks we like better than Sana Biotechnology
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
